JNJ - Cidara gains on dosing milestone in early-stage trial for flu candidate

San Diego, California-based biotech, Cidara Therapeutics (NASDAQ:CDTX) is trading ~11% higher in the pre-market after announcing the completion of dosing in the first cohort of the Phase 1 trial for CD388, an immunotherapy candidate designed for the prevention of seasonal and pandemic influenza. The randomized, double-blind, dose-escalation study was prepared to evaluate intramuscular and subcutaneous administration of CD388 in healthy subjects.  With the completion of the dosing in the first, low-dose cohort, Cidara (CDTX) plans to advance the trial to the next mid-dose cohort. Janssen unit of Johnson & Johnson (JNJ) has joined hands with the company to conduct the trial as part of an exclusive worldwide license and collaboration agreement between the two parties. The initial safety and pharmacokinetics data from the trial are anticipated in 2H 2022.

For further details see:

Cidara gains on dosing milestone in early-stage trial for flu candidate